Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04046185
Other study ID # ECCT001
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date October 1, 2019
Est. completion date October 1, 2022

Study information

Verified date August 2019
Source Shanghai First Maternity and Infant Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We want to make a comparison of PD-1 inhibitor combined with progesterone versus progesterone alone in the treatment of early stage endometrial cancer patients who want to preserve fertility.


Description:

Approximately 63,400 new cases of endometrial cancer are diagnosed annually in China. While the initial treatment for early-stage disease is surgical staging with lymphadenectomy, it is apparently inappropriate for young patients who want to preserve fertility. Currently the standardize treatment for these patients are high-dose progesterone, which will be effective in approximately 40~70% patients. Mirena have been used recently as a new available treatment option, however, no concrete evidence shows it is more effective than the traditional progesterone treatment.

PD-1 inhibitor has been utilized as a salvage treatment in many cancers including ovarian cancer, cervical cancer, lung cancer, gastric cancer and endometrial cancer. As endometrial cancer showed high microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) rates, it is assumed to be highly responsive to PD-1 inhibitor treatment. Published clinical trial results showed that PD-1 inhibitor treatment was effective in 6/24 late-stage endometrial cancer patients, with little or mild side effects. Here we want to investigate the efficacy of PD-1 inhibitor combined with progesterone in early stage endometrial cancer patients who want to preserve fertility.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date October 1, 2022
Est. primary completion date October 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Early endometrial cancer patients (cancer confined in the endometrium, endometrioid histology, G1-2)

2. Patients want to preserve fertility

3. Informed consent acquired

4. Age <18, >= 45

5. Eastern Cooperative Oncology Group (ECOG) performance status score <=1

6. Normal blood routine test

7. Normal hepatic and renal function

8. Normal thyroid function

9. Patients willing to accept three times of hysteroscopy: before treatment, 3 months after treatment, 6 months after treatment.

10. Pregnancy test negative before treatment

Exclusion Criteria:

1. Patients are receiving immune-checkpoint inhibitor therapy

2. Patients need or request to receive other anti-cancer drug treatment such as chemotherapy

3. Patients are allergic to immune-checkpoint inhibitor agents

4. Patients have abnormal blood routine test results or impaired hepatic and renal functions

5. Patients have a history of cardiovascular disease, including severe hypertension, frequent cardiac arrhythmia, history of myocardial infarction

6. Patients have a history of hepatitis B or hepatitis C infection, with detectable virus load

7. Severe obstructive lung disease

8. Autoimmune disease

9. Need to receive daily corticosteroid or other immune-inhibitory agents

10. Active tuberculosis patients

11. Patients have a history of other malignant tumors

12. Patients with acute infectious disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PD-1 inhibitor combined progesterone
Toripalimab combine with progesterone
progesterone
progesterone

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shanghai First Maternity and Infant Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologic complete remission rate of endometrial curettage tissues Hysteroscopy was performed 6 months after treatment. If the pathological results are normal, it is considered to be complete remission 6 months
Primary Pathologic partial remission rate of endometrial curettage tissues Hysteroscopy was performed 6 months after treatment. If the pathological results showed hyperplasia, it is considered to be partial remission 6 months
Secondary adverse effects side effects was evaluated every 2 weeks during treatment up to 1 year after treatment
Secondary pregnancy rate pregnancy rate was recorded after treatment up to 2 years after treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03469674 - PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer Phase 3
Not yet recruiting NCT06278857 - SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Phase 2
Recruiting NCT04792749 - Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer Phase 3
Completed NCT04972682 - [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer N/A
Recruiting NCT05179447 - PROfiling Based Endometrial Cancer Adjuvant Therapy N/A
Recruiting NCT04073706 - Sentinel Node Biopsy in Endometrial Cancer Phase 3
Recruiting NCT04291612 - Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Recruiting NCT06417736 - Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women N/A
Recruiting NCT04839614 - Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia N/A
Completed NCT03580421 - Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO) N/A